New advances in miRNA biomarker research, powered by BIDMC's Detection Unit

Two new studies, presented at HiRM and AACR, identified promising RNA biomarkers in breast cancer and Hodgkin lymphoma. At the heart of both efforts was the Detection Unit at BIDMC’s Precision RNA Medicine Core.

What made these discoveries possible?

High-throughput miRNA screening using Mirxes qPCR panels, quantifying up to 372 miRNAs per sample with precision and sensitivity.

Expert bioanalysis to uncover miRNA candidates with clinical or therapeutic relevance.

Whether you're exploring plasma RNA, working on early detection assays, or validating liquid biopsy markers, this is the core that can help translate your hypothesis into publishable data.